Literature DB >> 696818

Effect of somatostatin on myoelectrical activity of small bowel.

P Thor, R Król, S J Konturek, D H Coy, A V Schally.   

Abstract

Somatostatin, a growth hormone-release inhibiting hormone, has been found to be a powerful inhibitor of gastric and pancreatic secretion as well as of hormone release in the digestive system. This study was undertaken to determine the influence of somatostatin on the myoelectrical activity pattern of the small bowel. Three conscious dogs were prepared with electrodes spaced 25 cm apart along the entire small intestine. Intravenous infusions of somatostatin were administered in various doses (0.6--5.0 microgram/kg.h) while spike activity and slow waves were recorded under fasting conditions, after a meat meal, or during intravenous infusion of gastrin, caerulein, or insulin. Somatostatin at a dose of 0.6 microgram/kg.h almost doubled the frequency of the interdigestive myoelectric complex. Somatostatin in fed dogs caused a dose-dependent decrease of the normal fed spike activity, and at higher doses it induced a pattern like that seen in fasting animals. The slow-wave frequency in both fasted and fed conditions was not changed significantly. We conclude that somatostatin given under basal conditions increases the frequency of the interdigestive complex and, when administered after feeding, converts the fed-type pattern to the fasted-type pattern. It may therefore play a promoting role in initiating the interdigestive myoelectric complex.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 696818     DOI: 10.1152/ajpendo.1978.235.3.E249

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

1.  Postprandial disruption of migrating myoelectric complex in dogs. Hormonal versus extrinsic nervous factors.

Authors:  N S Hakim; M G Sarr; M P Spencer
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

2.  Amelioration of intestinal dysmotility and stasis by octreotide early after small-bowel autotransplantation in dogs.

Authors:  K Nakada; A Ikoma; T Suzuki; J C Reynolds; W L Campbell; S Todo; T E Starzl
Journal:  Am J Surg       Date:  1995-03       Impact factor: 2.565

3.  Somatostatin and the intestinal transport of glucose and other nutrients in the anaesthetised rat.

Authors:  C Daumerie; J C Henquin
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

4.  Effect of erythromycin on interdigestive gastrointestinal contractile activity and plasma motilin concentration in humans.

Authors:  O Kawamura; T Sekiguchi; M Kusano; T Nishioka; Z Itoh
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

5.  Gastrointestinal secretory, motor, circulatory, and metabolic effects of prosomatostatin.

Authors:  S J Konturek; J Tasler; J Jaworek; W Pawlik; K M Walus; V Schusdziarra; C A Meyers; D H Coy; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

6.  Motilin regulation of canine interdigestive intestinal motility.

Authors:  M G Sarr; K A Kelly; V L Go
Journal:  Dig Dis Sci       Date:  1983-03       Impact factor: 3.199

7.  Effect of SMS 201-995 on exocrine pancreatic secretion in a patient with external pancreatic fistula.

Authors:  T Ohta; T Nagakawa; K Mori; M Kanno; M Kayahara; K Ueno; I Miyazaki
Journal:  Int J Pancreatol       Date:  1992-06

8.  Erythromycin induces migrating motor complex in human gastrointestinal tract.

Authors:  T Tomomasa; T Kuroume; H Arai; K Wakabayashi; Z Itoh
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

9.  Pancreatic polypeptide and intestinal motility in dogs.

Authors:  P J Thor; J W Konturek; S J Konturek
Journal:  Dig Dis Sci       Date:  1987-05       Impact factor: 3.199

10.  Mediation by SRIF1 receptors of the contractile action of somatostatin in rat isolated distal colon; studies using some novel SRIF analogues.

Authors:  E S McKeen; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.